Carbidopa monohydrate

Carbidopa is the hydrate of 3-(3,4-dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used in the management of Parkinson’s disease to reduce peripheral adverse effects of levodopa. Among its listed roles, it functions as a antiparkinson drug, a dopaminergic agent, an EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor and an antidyskinesia agent. It belongs to the class of hydrazines, a monocarboxylic acid, a member of catechols and a hydrate. It includes a carbidopa (anhydrous). It is grouped under the following drug class(es): Dopamine agents. Its therapeutic use is listed as central nervous system (CNS) agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Carbidopa Monohydrate and Carbidopa hydrate. Its PubChem CID is 38101.